We applied a novel application of T2 mapping in a longitudinal study to evaluate whether MRI relaxometry may hold more potential than current measures for portending breast-cancer-treatment-related-lymphedema (BCRL) progression. Baseline biophysical and T2 measurements were performed in patients following lymph node removal. Patients were then monitored for BCRL progression (duration=two years). Baseline descriptive (age, BMI, number of nodes removed) and biophysical (bioimpedance, tissue dielectric, and arm volume) measures did not discriminate between patients who did vs. did not progress, yet baseline T2 was regionally elevated in those who progressed. MRI relaxometry may serve as a tool to identify BCRL risk.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords